Trailing Twelve Months Revenue Growth: BioXcel Therapeutics Corp (BTAI)

Brandmark of BioXcel Therapeutics Corp (BTAI)

BioXcel Therapeutics is expanding the reach of its drug Igalmi and implementing AI platforms within neurology. The year-over-year dynamics of core revenue over a rolling 12-month period illustrate these processes, where -14.50 characterizes this valuation parameter. Management is currently restoring compliance following regulatory claims. Financial success depends on pharmacy coverage and the medical community's recognition of the therapy.

BioXcel Therapeutics (BTAI): Revenue Growth YoY (Last 12 Months) from 02/11/2024 to 09/19/2026

BioXcel Therapeutics Inc (BTAI) - metric breakdowns and financial figures

- stock price and consensus target price:
- company stock exchange capitalization indicators:
Analysis of all company metrics:BioXcel Therapeutics
Manufactured products of BioXcel Therapeutics, Inc.

This indicator measures revenue dynamics, allowing for a real-time assessment of business expansion rates. By analyzing year-over-year sales growth over a rolling four-quarter period, investors can identify the current trend between official reports. The calculation is based on the percentage change in revenue over the last twelve months. For BioXcel Therapeutics (BTAI), this metric reflects the commercialization efficiency of the drug Inertia. Slow product penetration into the niche market is limiting the indicator's upward momentum.